Patent Trial and Appeal Board Denies IPR Petition Aimed at ParkerVision '342 Patent

01.08.2015 - 1:30 PM

JACKSONVILLE, Fla., Jan. 8, 2015 -- ParkerVision, Inc. (Nasdaq:PRKR), a developer and marketer of semiconductor technology solutions for wireless applications, today announced that on January 8, 2015, the Patent Trial and Appeal Board ("PTAB") denied institution of trial of all challenged claims for Inter Partes review ("IPR") of ParkerVision patent 7,496,342 ("the '342 patent"). The IPR petition was filed in July, 2014 by RPX Corporation and Michael Farmwald against five claims of the '342 patent. The '342 patent is one of the four patents subject to ParkerVision's pending appeal in its patent infringement case against Qualcomm, Incorporated.

Jeffrey Parker, Chairman and CEO, commented, "We applaud the PTAB's decision to deny this entire IPR petition. Both the district court and now the PTAB have rejected questions of validity with regard to this patent, and we believe that is an appropriate and just determination. Claim 18 of the '342 patent is one of the eleven claims that a district court jury found to be infringed by Qualcomm. Denial of trial institution for this and all of the other challenged claims of the '342 patent is an extremely favorable disposition for ParkerVision in its ongoing legal battle with Qualcomm."

About ParkerVision

ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies that enable advanced wireless solutions for current and next generation communications networks. Protected by a highly-regarded, worldwide patent portfolio, the Company's solutions for wireless transfer of RF waveforms address the needs of a broad range of wirelessly connected devices for high levels of RF performance coupled with best-in-class power consumption. For more information please visit www.parkervision.com. (PRKR-G).

Safe Harbor Statement

This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports, including the Form 10K for the year ended December 31, 2013 and the Forms 10Q for the quarters ended March 31, June 30, and September 30, 2014. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

CONTACT: Cindy Poehlman
         	Chief Financial Officer
         	ParkerVision, Inc.
         	904-732-6100, cpoehlman@parkervision.com
         	or
         	Don Markley or Glenn Garmont
			The Piacente Group
			212-481-2050, parkervision@tpg-ir.com